An appeals court has rejected Chinese radio manufacturer Hytera’s challenge to a finding it misappropriated the source code of US mobile phone giant Motorola.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
Element Zero has denied claims that three former Fortescue employees, including one executive, misused confidential information and developed a green iron process on the company dime.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
Green iron start-up Element Zero is continuing its fight over search orders won by rival Fortescue that it claimed were a massive over-reach.
Fortescue has defeated a bid by its former CFO’s green iron start-up to set aside search orders that were said to have been secured “off the back of egregious material non-disclosure”.
Samsung Bioepis can’t get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug.
A judge has found ASX-traded mining equipment manufacturer Austin Engineering can use documents disclosed in its case against rival Schlam over a former employee’s alleged leak of confidential business information to expand its claims.
Fortescue has rejected Element Zero’s “implausible” claims that the start-up’s founder was instructed by the mining giant’s IP manager to access and delete certain documents after his resignation, as it defends allegations that search orders it won over the alleged misappropriation of its confidential information were based on weak evidence.